A recent report by 17:30 Live Rheinland-Pfalz/Hessen featured a new approach from cancer research in Frankfurt: Prof. Volker Dötsch, PROXIDRUGS researcher, and Dr. Andreas Joerger are working to stabilize mutated variants of the tumor suppressor protein p53. p53 is often referred to as the “guardian of the genome” because it can detect damaged cells and activate important protective mechanisms. In many tumors, however, p53 is mutated and loses its function. One central problem is that many of...

Dr. Johannes Dreizler was awarded the 2026 Kurt Ruths Prize by TU Darmstadt. Endowed with €12,000, the prize recognizes outstanding scientific achievements by early-career researchers. Johannes Dreizler earned his PhD at the Department of Chemistry at TU Darmstadt in the research group of PROXIDRUGS project leader Prof. Felix Hausch. In his dissertation, he developed novel molecular glues for targeted cancer therapy. These compounds bring disease-relevant target proteins into close proximity...

From climate-neutral industry and new mobility solutions to global health research: Germany’s innovation clusters are developing the ideas that will shape our society tomorrow. At re:publica 2026, the cluster and campus initiatives of the Federal Ministry of Research, Technology and Space (BMFTR) will, for the first time, jointly showcase their success stories. The PROXIDRUGS Cluster, based at Goethe University Frankfurt, is developing innovative drugs that can selectively degrade...